Enamel Matrix Derivative: Preclinical Biologic Background

Richard J. Miron,Anton Sculean,David L. Cochran,Nikos Donos,James Deschner,Michel Dard,Yufeng Zhang,Adrian Kasaj,Yoshinori Shirakata,Dieter D. Bosshardt

2019-01-01

Abstract:Twenty years ago, the use of biologic agents and growth factors was not common in regenerative dentistry. Dating back to a series of publications in 1997, it was shown that the use of enamel matrix proteins could serve as key regenerative proteins capable of promoting periodontal regeneration including new cementum, with functionally oriented inserting new periodontal ligament (PDL) fibers, and new alveolar bone formation. Today nearly 1,000 publications have investigated enamel matrix derivate (EMD, Erndogain [Straumann]) as an agent capable of regenerating the periodontium. These experiments predated the use of recombinant human growth factors in dentistry. Original experiments led by Lars Hammarstrom paved the way to an enormous number of publications related to the use of biologic agents in dentistry. Twenty years later, it is clear that all of these studies have greatly contributed to our understanding of how biologics can act, as mediators for either periodontal or bone regeneration and have provided additional clinical means to support tissue regeneration of the periodontium. This chapter aims to (1) provide the biologic background necessary to understand the rationale for using EMD for periodontal regeneratiOn, (2) present animal and human histologic evidence of periodontal regeneration following EMD application, and (3) discuss future avenues of research in this field.